US Exchange Filings

Mentari Therapeutics Appoints Deloitte as Auditor Following Merger

Mentari Therapeutics has replaced both predecessor companies’ auditors with Deloitte for 2026, following its merger with InMed. Investors should note that earlier audits flagged substantial doubt about both businesses’ ability to continue as going concerns—a concern the auditor change does not resolve.

Mentari Therapeutics has replaced both accounting firms that audited its predecessor businesses, appointing Deloitte & Touche to audit the combined company’s financial statements for the year ending December 31, 2026. The changes follow Mentari’s November 6 business combination with the former InMed Pharmaceuticals, which is now the public company named Mentari Therapeutics.

  • Both predecessor auditors were dismissed on November 17. CBIZ CPAs had audited InMed, while Ernst & Young had audited Mentari before the combination. The company’s audit committee approved both dismissals.
  • Deloitte was engaged on November 19 as the combined company’s independent auditor for the fiscal year ending December 31, 2026.
  • The prior audit reports included going-concern warnings. CBIZ’s reports on InMed’s fiscal 2025 and 2026 financial statements, and EY’s report on Mentari’s 2025 financial statements, each included an explanatory paragraph saying substantial doubt existed about the relevant business’s ability to continue as a going concern. The reports were not adverse or disclaimed, and were not otherwise modified for accounting principles, audit scope or uncertainty.
  • The auditor changes were not attributed to disputes. The company said there were no disagreements with either CBIZ or EY over accounting, financial-statement disclosures or audit procedures, and no reportable events during the periods covered.
  • Deloitte had not previously advised the businesses on specified accounting or audit matters during the periods described.

The merger was accounted for as a reverse recapitalization, with Mentari treated as the accounting acquirer. As a result, Mentari’s historical financial statements became the historical financial statements of the public company. That context helps explain why the combined company is moving on from the two firms that audited its predecessor businesses.

The auditor transition itself does not resolve the going-concern warnings in the predecessor companies’ prior reports. Those warnings are historical findings; the announcement does not provide an updated assessment of the combined company’s ability to continue as a going concern.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.